Zydus Cadila gets USFDA nod to market phosphorus controlling drug

Topics Zydus Cadila | USFDA

Drug firm Zydus Cadila on Thursday said it has received final nod from the US health regulator to market generic Sevelamer Carbonate tablets, indicated for control ofphosphorusinpeoplewith chronic kidney disease who are on dialysis,in the American market.

The company has received final approval from the United States Food and Drug Administration (USFDA)to market Sevelamer Carbonate tabletsin the strength of 800 mg, Zydus Cadila said in a filing to the BSE.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, it added.

The drug is used to control phosphorus levels in people with chronic kidney disease who are on dialysis. It helps prevent hypocalcemia (low levels of calcium in the body) caused by elevated phosphorus, Zydus Cadila said.

The group now has 296 approvals and has so far filed over 390abbreviated new drug applications (ANDAs) since the commencement of its filing process, it said.

Shares of Cadila Healthcare, the listed entity of the group, closed 0.16 per cent higher at Rs385.90per scrip on the BSE on Thursday.


(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)


Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel